Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 25 May 2016
Price : $35 *
At a glance
- Drugs Dexanabinol (Primary)
- Indications Brain cancer; Glioma; Malignant melanoma; Solid tumours
- Focus Adverse reactions
- Sponsors e-Therapeutics
- 09 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Feb 2014 The first patient has been dosed and completion is expected in quarter 4, 2014, according to an e Therapeutics media release.
- 10 Feb 2014 Status changed from planning to recruiting, as reported by an e Therapeutics media release.